Horizon Therapeutics plc Overview
Pro stress-test →Horizon Therapeutics was a global biopharmaceutical company focused on researching, developing, and commercializing medicines for rare diseases, autoimmune conditions, and severe inflammatory diseases. The company was acquired by Amgen in December 2023 and is no longer independently traded. Prior to acquisition, Horizon operated through Orphan and Rheumatology and Inflammation segments with key commercial medicines including KRYSTEXXA, TEPEZZA, and UPLIZNA.
Strategic Profile
Pro stress-test →Horizon positioned itself as a high-growth biotech company specializing in orphan and rare disease therapeutics, with strong commercial execution in immunomodulation. The company demonstrated consistent double-digit revenue growth and operated manufacturing facilities in Ireland, reflecting a regional presence in biopharma development.
Competitive Landscape
Pro stress-test →Horizon competed in the rare disease and rheumatology therapeutics markets against other specialty pharma companies and biopharmaceutical firms. Primary competitors included other orphan drug developers and rheumatology specialists, though the company differentiated through focused immunomodulation strategy and strong commercial execution in niche markets.
Industry Context
Horizon Therapeutics plc operates in Rare disease biopharmaceuticals.
Key facts
Founded: 2008 · Headquarters: Dublin, Ireland · Employees: N/A · Revenue: $1.9B+ (pre-acquisition) · Market cap: N/A (Acquired December 2023)